

Acquisition of acute HCV in HIV-infected subjects is associated with cerebral disturbances but not increased microglial cell activation: a PET study

<u>Lucy Garvey</u>, Anil Ramlackhansingh, Joanna M Allsop, Emma Thomson, Janice Main, Ranjababu Kulasegaram, David Brooks, Simon Taylor-Robinson, Nicola Pavese, Alan Winston

Background

Fatigue frequently reported in chronic HCV monoinfection¹


Investigation of biological mechanism:

-HCV RNA detected in CSF and brain tissue^{2,3} -increased microglial cell activation⁴ and neuroinflammation^{5,6} -cognitive impairments^{6,7}

Now generally accepted despite potential confounders:

-depression,'diagnosis effect', drug use, hepatic encephalopathy -independent of drug-use or liver disease severity and reverse with SVR⁸


> [1]NEJM (1995) 332(22):1463-6 [2] J Virol 76(19): 10064-8 [3] J Neurovirol 14(1): 17-27 [4] J Hepatol 49(3): 316-22 [5] J Hepatol 41(5): 845-51 [6] J Hepatol (2002) 39(6):812-6 [7] Lancet 358(9275): 38-9 [8] [HIV Med 8(8): 520-6





Aim

To investigate the effect of acute HCV in HIV-infected subjects upon cerebral function:

- -cognitive performance
- -cerebral metabolites using MR-spectroscopy
- -microglial cell activation using PET scans








<section-header><section-header><text><figure><figure><figure>

Results						
	Number, n	Acute HCV/HIV 24	HIVmonoinfection 57			
Patient demographics	Age (years), median [IQR]	41 [36, 44]	47 [39, 56]			
	Male gender, n(%)	24 (100)	50 (89)			
	Time-elapsed since HIV diagnosis (years), median [IQR]	6 [3, 12]	11 [5, 16]			
HIV disease parameters	Current CD4+(cells/µL), median [IQR]	590 [458, 745]	505 [382, 783]			
	Nadir CD4+(cells/µL), median [IQR]	200 [215, 395]	205 [88, 283]			
	Receiving antiretroviral therapy, n (%)	17 (71)	54 (95)			
	Current plasma HIV RNA <50 c/mL, n (%)	16 (67)	54 (95)			
	HIV VL of remaining subjects (c/mL), median	17099	14182			
Acute HCV parameters	Time elapsed since negative HCV RNA (weeks), median [IQR]	24 [20, 32]	-			
	Current ALT (IU), median [IQR]	213 [78, 237]				
	Peak ALT (IU), median [IQR]	237 [180, 820]				
	HCV genotype, n (%)					
	1	21 (88)				
	2	0				
	3	1(4)				
	4 Most recent HCV PCR, copies/mL, median	2 (8) 3 849 936				



Results -	s – Cognitive Assessment			
	Acute HCV versus HIV monoinfection study group			
	<i>p</i> -value	95% CI		
Composite Z-score	0.68	[-1.38, 0.90]		
Cognitive speed score	0.05	[-0.99, 0.01]		
Accuracy score	0.20	[-0.18, 0.83]		
Executive function	0.02	[0.09, 1.07]		


Results – Cognitive assessment: executive function


Parameter	Univariate analysis		Multivariate analysis	
	<i>p</i> -value	95% CI	<i>p</i> -value	95% CI
Acute HCV	0.02	[0.09, 1.07]	<0.001	[0.55, 1.60]
Nadir CD4+ count, per 100 cell/uL increase	0.09	[-0.30, 0.02]	0.001	[-0.42, -0.10]
Current CD4+ count, per 100 cell/uL increase	0.70	[-0.12, 0.08]	-	
Age, per 10 year increase	0.68	[-0.28, 0.18]	-	
Receiving cART	0.70	[-0.95, 0.65	-	
Receiving NNRTI-based cART	0.38	[-0.65, 0.25]	-	
Time since HIV diagnosis, per 10 year increase	0.34	[-0.06, 0.02]	-	
CPE score	0.49	[-0.22, 0.45]	-	

Results – MR Spectroscopy

Basal ganglia location		Acute HCV study group unadjusted analyses		Acute HCV study group adjusted analyses		and the second s	
		<i>p</i> -value	95% CI	<i>p</i> -value	95% CI		
Cerebral m	etabolite ratio					A A A A A A A A A A A A A A A A A A A	
N-ac	etyl aspartate/Cr	0.54	[-0.45, 0.84]	-		est	
	Choline/Cr	0.36	[-2.27, 0.85]	-		die Cr	
	myo-Inositol/Cr	0.06	[-0.03, 1.32]	0.03	[0.02, 0.35]	how were how h	

Elevated myo-inositol is objective marker of neuroinflammation





Summary

Acute HCV coinfection associated with cerebral disturbances -poorer executive function -increased cerebral inflammatory metabolites

Similar changes previously described in chronic HCV monoinfection

Did not demonstrate increased *PK-11195* binding (differs from chronic HCV monoinfection)

Possible explanations

Microglial recruitment may occur more slowly or ligand not sensitive for acute changes (median 20 weeks since negative HCV RNA)

Microglial-cell activation may not be responsible and cerebral disturbances due to systemic circulating cytokines and fatigue

Future work to assess correlation of cerebral disturbances with Rx outcomes and longitudinal progression required

Acknowledgements

All volunteers who participated in study

Staff at HIV Department, St Mary's Hospital, London

Staff at MRC Robert Steiner Imaging Sciences Unit and Cyclotron Nuclear Medicine Unit, Hammersmith Hospital, Imperial College, London